Charmacy Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Charmacy Pharmaceutical CEO'su Chuanglong Yao, Mar2000 tarihinde atandı, in görev süresi 24.67 yıldır. in toplam yıllık tazminatı CN¥ 728.07K olup, şirket hissesi ve opsiyonları dahil olmak üzere 87.4% maaş ve 12.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 31.97% ine doğrudan sahiptir ve bu hisseler HK$ 319.75M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 5.7 yıldır.

Anahtar bilgiler

Chuanglong Yao

İcra Kurulu Başkanı

CN¥728.1k

Toplam tazminat

CEO maaş yüzdesi	87.4%
CEO görev süresi	24.7yrs
CEO sahipliği	32.0%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29

CEO Tazminat Analizi

Chuanglong Yao'un ücretlendirmesi Charmacy Pharmaceutical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥52m
Mar 31 2024	n/a	n/a	CN¥52m
Dec 31 2023	CN¥728k	CN¥636k	CN¥51m
Sep 30 2023	n/a	n/a	CN¥74m
Jun 30 2023	n/a	n/a	CN¥96m
Mar 31 2023	n/a	n/a	CN¥93m
Dec 31 2022	CN¥732k	CN¥638k	CN¥90m
Sep 30 2022	n/a	n/a	CN¥54m
Jun 30 2022	n/a	n/a	CN¥18m
Mar 31 2022	n/a	n/a	CN¥20m
Dec 31 2021	CN¥679k	CN¥646k	CN¥23m
Sep 30 2021	n/a	n/a	CN¥29m
Jun 30 2021	n/a	n/a	CN¥36m
Mar 31 2021	n/a	n/a	CN¥38m
Dec 31 2020	CN¥685k	CN¥649k	CN¥41m
Sep 30 2020	n/a	n/a	CN¥35m
Jun 30 2020	n/a	n/a	CN¥29m
Mar 31 2020	n/a	n/a	CN¥34m
Dec 31 2019	CN¥714k	CN¥650k	CN¥40m
Sep 30 2019	n/a	n/a	CN¥41m
Jun 30 2019	n/a	n/a	CN¥42m
Mar 31 2019	n/a	n/a	CN¥44m
Dec 31 2018	CN¥715k	CN¥649k	CN¥45m
Sep 30 2018	n/a	n/a	CN¥46m
Jun 30 2018	n/a	n/a	CN¥47m
Mar 31 2018	n/a	n/a	CN¥46m
Dec 31 2017	CN¥713k	CN¥650k	CN¥45m

Tazminat ve Piyasa: Chuanglong 'nin toplam tazminatı ($USD 100.51K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 233.11K ).

Tazminat ve Kazançlar: Chuanglong 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chuanglong Yao (54 yo)

24.7yrs

Görev süresi

CN¥728,071

Tazminat

Mr. Chuanglong Yao has been Chief Executive Officer at Charmacy Pharmaceutical Co., Ltd. since March 2000 and serves as its Vice Chairman since May 31, 2023 and served as its Chairman since May 2015. Mr. Y...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chuanglong Yao	CEO & Vice Chairman	24.7yrs	CN¥728.07k	31.97% HK$ 319.7m
Hanzi Zhang	CFO & Executive Director	2.6yrs	CN¥385.49k	Veri yok
Yuyan Zheng	VP & Executive Director	9.3yrs	CN¥991.13k	Veri yok
Zhijie Lin	Chief Logistics Officer & CTO	no data	CN¥188.00k	Veri yok
Wai Ling Wong	Joint Company Secretary	2.6yrs	Veri yok	Veri yok
Jiexi Yao	Joint Company Secretary	2.6yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: 2289 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chuanglong Yao	CEO & Vice Chairman	24.7yrs	CN¥728.07k	31.97% HK$ 319.7m
Hanzi Zhang	CFO & Executive Director	2.3yrs	CN¥385.49k	Veri yok
Yuyan Zheng	VP & Executive Director	9.5yrs	CN¥991.13k	Veri yok
Chi Wai Wan	Independent Non-Executive Director	8.9yrs	CN¥144.00k	Veri yok
Jian Guan	Independent Non-Executive Director	8.9yrs	CN¥50.00k	Veri yok
Ling Zhang	Independent Supervisor	9.5yrs	Veri yok	Veri yok
Xiyue Zheng	Employee Representative Supervisor	9.5yrs	Veri yok	Veri yok
Hanguo Li	Independent Non-Executive Director	1.5yrs	CN¥29.30k	Veri yok
Zheng Fu	Non-Executive Director	2.3yrs	Veri yok	Veri yok
Jingbin Yan	Non-Executive Chairman	2.4yrs	Veri yok	Veri yok
Fei Xu	Non-Executive Director	1.5yrs	Veri yok	Veri yok
Minghong Zhu	Chairman of the Board of Supervisors	1.5yrs	Veri yok	Veri yok

5.7yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2289 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Charmacy Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Recent updates

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1H 2023)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

New major risk - Financial position

Charmacy Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 10 July 2024

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 18%

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 31%

Investor sentiment improves as stock rises 19%

New major risk - Earnings quality

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

First half 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.19 in 1H 2022)

Investor sentiment improves as stock rises 23%

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Upcoming dividend of HK$0.50 per share at 6.0% yield

Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Upcoming dividend of CN¥0.45 per share at 6.2% yield

Charmacy Pharmaceutical Co., Ltd. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on July 31, 2023

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.24 in 1H 2021)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Investor sentiment improved over the past week

Insufficient new directors

Charmacy Pharmaceutical Co., Ltd. Announces Change in Board of Directors and Composition of Board Committees

Full year 2021 earnings released

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

Charmacy Pharmaceutical Co., Ltd. to Distribute the Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of CN¥0.20 per share

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.37 in FY 2019)

Full year 2020 earnings released

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$4.40

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

New 90-day low: HK$4.43

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Investor sentiment improved over the past week

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

First half earnings released

New 90-day low: HK$4.49

First half earnings released

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

New 90-day low - HK$5.12

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat